Clinical Trial Update: Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of LNP023 (iptacopan) in primary IgA nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• LNP023 (iptacopan) (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: IgA Nephropathy | Phase 3 | Status: COMPLETED